Venus Medtech (Hangzhou) (HKSE:02500) Capital Expenditure : HK$-287.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Venus Medtech (Hangzhou)'s cash flow for capital expenditures for the six months ended in Dec. 2023 was HK$-227.4 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-287.56 Mil.

Venus Medtech (Hangzhou) Capital Expenditure Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Capital Expenditure Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

Get a 7-Day Free Trial

-27.30

-147.05

-177.75

-199.64

-287.56

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capital Expenditure	Get a 7-Day Free Trial							-145.37	-224.12	13.87	-60.21	-227.35

Venus Medtech (Hangzhou) Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-287.56 Mil.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines